Novel Binder Lowers Phosphorus, LDL Cholesterol
An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.
Renal Week 2010 Hyperphosphatemia
Phosphate, FGF-23 Rise in PD Patients as Residual Renal Function Declines
Serum phosphate and fibroblast growth factor 23 (FGF-23) levels increase in incident peritoneal dialysis (PD) patients increase as residual renal function declines, according to researchers who presented their findings at Renal Week 2010 in Denver.
High Phosphocalcic Product May Rule Out Transplants
A high phosphocalcic product significantly increases the risk of non- eligibility for a kidney transplant among adults with end-stage renal disease (ESRD), Canadian researchers concluded in a study presented at Renal Week 2010 in Denver.
High Phosphorus May Predict Faster CKD Progression
High baseline serum phosphorus levels in CKD patients may predict an increased likelihood of renal disease progression and death, according to Italian investigators, who presented their findings at Renal Week 2010 in Denver.
Elderly Men with CKD Are at Greater Death Risk
Among elderly patients with CKD, female gender and lower estimated glomerular filtration rate (eGFR) predict a higher risk of progressing to end-stage renal disease (ESRD), whereas male gender and a history of peripheral vascular disease are associated with an increased likelihood of death, according to a study presented at Renal Week 2010 in Denver.
Niacin for Phosphorus Lowering Benefits Diabetics
Niacin treatment is known to lower phosphorus levels in patients with stage 5 CKD and hyperphosphatemia, but new findings show that this effect extends across a broad spectrum of renal function in patients with type 2 diabetes without stage 4 or 5 CKD, researchers reported at Renal Week 2010 in Denver.
High Phosphorus Raises Death Risk in Peritoneal Dialysis Patients
Hyperphosphatemia is associated with an increased six-year mortality risk in patients on chronic peritoneal dialysis (CPD), according to data shown at Renal Week 2010 in Denver.
Phosphate-Binder Choice Could Impact Missed Dialysis Sessions
Use of sevelamer rather than calcium-based calcium binders (CBBs) to treat hyperphosphatemia in dialysis patients is associated with a reduction in missed in-center dialysis treatments regardless of dialysis organization size, according to findings published in abstract form as part of Renal Week 2010 in Denver.
Novel Iron-Based Phosphate Binder Effective, Well Tolerated
An experimental iron-based phosphate binder is effective for treating hyperphosphatemia in hemodialysis (HD) patients, and is well tolerated, according to new data shown at Renal Week 2010 in Denver.
New Finding May Shed Light on Phosphorus-CVD Link
Serum phosphorus is independently associated with angiopoietin 2 in renal transplant patients, and this could help explain why high serum phosphorus levels increase the risk of cardiovascular disease (CVD), according to investigators who presented a study at Renal Week 2010 in Denver.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Renal Week 2010 Hyperphosphatemia
Loading... 
Loading...